Issue
Korean Journal of Chemical Engineering,
Vol.32, No.4, 576-582, 2015
Effect of an ionic liquid on vancomycin crystallization
We first developed a vancomycin crystallization process using an ionic liquid (IL) and improved the crystallization efficiency by optimization of crystallization conditions (pH, conductivity, solution of distilled water and IL/acetone ratio, crystallization temperature, IL concentration). We also investigated the effect of major process parameters on crystallization, using an electron microscope, and identified morphology by XRD analysis. Using ILs (1-butyl-3- methylimidazolium tetrafluoroborate ([BMIm][BF4]), 1-butyl-3-methylimidazolium hexafluorophosphate ([BMIm] [PF6])), vancomycin crystals were successfully formed under the optimal crystallization conditions: pH 4.5; conductivity, 10 mS/cm; solution of distilled water and IL/acetone ratio, 1 : 3.5 (v/v); crystallization temperature, 10 oC; IL concentration, 20% (v/v). When using an IL ([BMIm][BF4]), the time required for crystallization in the existing crystallization methods (~24 hr) was dramatically decreased (~9 hr) and high-quality vancomycin crystals were successfully formed.
[References]
  1. Yan H, Qi D, Cheng X, Song Z, Li W, He B, J. Antibiot., 51, 750, 1998
  2. Griffith RS, J. Antimicrob. Chemoter., 14, 1, 1984
  3. Kim SI, Han CY, Jung HS, Lee JS, Ok SY, Kim SC, Korean J. Anesthesiol., 51, 727, 2006
  4. United States Pharmacopoeia (USP 29), Vancomycin hydrochloride, United State Pharmacopeial Convention, Inc. (2006)., 2006
  5. Javadzadeh Y, Mohammadi A, Khoei N, Nokhodchi A, Acta Pharmacol. Sin., 59, 187, 2009
  6. Kim SI, Jeong KE, Jeong SY, Kim CU, J. Korean Oil Chem. Soc., 25, 232, 2008
  7. Kim WS, Lee EK, Korean J. Biotechnol. Bioeng., 20, 164, 2005
  8. Kim KJ, Prospect. Ind. Chem., 4(4), 1, 2001
  9. Lee JY, Lee KH, Chae HJ, Kim JH, Korean J. Chem. Eng., 27(5), 1538, 2010
  10. Kim YN, Lee JY, Kim JH, Process Biochem., 46, 2068, 2011
  11. Kwak EA, Kim SJ, Kim JH, Korean J. Chem. Eng., 29(11), 1487, 2012
  12. Kroon MC, Toussaint VA, Shariati A, Florusse LJ, Spronsen JV, Witkamp GJ, Peters CJ, Green Chem., 10, 333, 2008
  13. Tang B, Bi W, Tian M, Row KH, J. Chromatogr. B, 904, 1, 2012
  14. Li XX, Xu XD, Dan YY, Zhang ML, Crystallogr. Rep., 54, 1285, 2009
  15. Judge RA, Takahashi S, Longenecker KL, Fry EH, Zapatero CA, Chi ML, Cryst. Growth Des., 9, 3463, 2009
  16. Wang Z, Fang W, Li Y, Zhang J, Gu Q, Korean J. Chem. Eng., 31(6), 919, 2014
  17. Hebel D, Urdingen M, Hekmat D, Botz DW, Cryst. Growth Des., 13, 2499, 2013
  18. Pusey ML, Paley MS, Turner MB, Rogers RD, Cryst. Growth Des., 7, 787, 2007
  19. Lee JW, Jung YT, Suh JW, Lee KS, US Patent, 7,018,814 (2006)., 2006
  20. Food US, Drug Administration, Vancomycin solubility study, Report to office of generic drugs; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm082291.pdf (2008)., 2008
  21. Claudius JS, Neau SH, Int. J. Pharm., 168, 41, 1998
  22. Kim SJ, Kim JH, Korean J. Chem. Eng., 10.1007/s11814-014-0222-0., 2014
  23. Freire MG, Santos LMNBF, Fernandes AM, Coutinho JAP, Marrucho IM, Fluid Phase Equilib., 261(1-2), 449, 2007
  24. Garcia-Ruiz JM, Gonzalez-Ramirez LA, Gavira JA, Otalora F, Acta Crystallogr. Sect. D-Biol. Crystallogr., 58, 1638, 2002